 |
answer text |
<p>There are <del class="ministerial">two</del> <ins class="ministerial">three </ins>human
papilloma virus vaccines licensed in the European Union: Cervarix<ins class="ministerial">,</ins>
<del class="ministerial">and</del> <ins class="ministerial">Gardasil and </ins>Gardasil
9. These products are licensed centrally throughout Europe by the European Commission
via the European Medicines Agency (EMA). Applicants for centrally authorised products
are required to submit all relevant supporting clinical trials data, whether published
or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory
Agency.</p><p> </p><p>Under current medicines legislation, the EMA database registers
all EU-approved clinical trials of investigational medicinal products. Since March
2011 this information has been publicly accessible through the EU Clinical Trials
Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all
EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented
and can be found here:</p><p> </p><p><a href="https://www.clinicaltrialsregister.eu/ctr-search/search"
target="_blank">https://www.clinicaltrialsregister.eu/ctr-search/search</a></p><p>
</p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide
a summary of their trial results uploaded onto the EU Clinical Trials Register within
one year of their trial completing. There is a two year programme of back-loading
underway to provide summaries of trial results for all trials on the Register back
to when the EudraCT database was initiated in May 2004.</p>
|
|
